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A COST UTILITY ANALYSIS OF ERLOTINIB IN PATIENTS
WITH PREVIOUSLYTREATED ADVANCED NON-SMALL-CELL
LUNG CANCER (NSCLC)
Bradbury PA1, Jang R1, Isogai P2, Ng R1, Mittmann N2, Evans W3,
Shepherd FA1, Leighl NB1
1Princess Margaret Hospital/University Health Network,Toronto, ON,
Canada, 2HOPE Research Centre,Toronto, ON, Canada, 3Juravinski
Cancer Centre, Hamilton, ON, Canada
OBJECTIVE: Erlotinib, a novel targeted anticancer therapy,
improves survival and quality of life (QoL) in patients with
advanced NSCLC after chemotherapy failure. The incremental
cost effectiveness ratio (ICER) of erlotinib based on a random-
ized placebo-controlled trial, (NCIC CTG BR.21) is $95,869
(2007 CDN), per life-year gained (LYG). Here we perform a cost
utility analysis (CUA) of erlotinib in patients with advanced
NSCLC, and explore novel methodology to utilize QoL data
collected using the EORTC QLQC30 tool. METHODS: Previ-
ously published resource utilization and QoL data from patients
recruited as part of the NCIC CTG BR.21 clinical trial were used.
Utility weights were derived from the prospective collection of
the EQ5D in a separate cohort of advanced NSCLC patients
receiving erlotinib or supportive care alone. QoL was also pro-
spectively collected using the EORTC QLQC30. Correlation
between utility (EQ5D) and QoL in the cohort is being explored,
and will be applied to published QoL data from the NCIC CTG
BR.21 trial data. RESULTS: Prospective data from the EQ5D
and EORTC QLQC30 were obtained from 64 patients with
NSCLC, 31 receiving erlotinib and 33 supportive care. The mean
utility derived for those treated with erlotinib was 0.772, and for
those not receiving erlotinib was 0.754. The mean incremental
cost of erlotinib over supportive care was previously derived as
$12,303, mean survival 0.13 years, and quality-adjusted survival
improvement with erlotinib treatment in advanced NSCLC based
on published data from the NCIC CTG BR.21 trial was esti-
mated at 0.11 QALY, with an ICER estimated at approximately
$110,321 per QALY CONCLUSION: The cost utility of erlo-
tinib in patients with advanced NSCLC is estimated at $110,321
per QALY (CDN$ 2007); a parallel investigation to evaluate
methodology to utilize EORTC QLQ30 QoL data is underway.
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TIME COSTS AND OUT-OF-POCKET COSTS OF PROSTATE
CANCER SURVIVORS IN ONTARIO, CANADA
Carcone SM1, Bremner KE1, Kowgier ME2, Krahn MD1
1University Health Network,Toronto, ON, Canada, 2University of
Toronto,Toronto, ON, Canada
OBJECTIVE: To estimate out-of-pocket costs (OPC) and time
costs (TC) for prostate cancer (PC) care in PC survivors.
METHODS: Surviving PC patients residing in Ontario, and diag-
nosed in 1993–4, 1997–8, or 2001–2, were selected from the
Ontario Cancer Registry (n = 1961). A self-report questionnaire
was completed, which asked about health care and lost time
associated with PC in eight key areas: 1) health care professional
visits, and accompanying person; 2) medication use; 3) equip-
ment purchased; 4) community service use; 5) employment time
lost; 6) problems with household chores; 7) leisure time lost;
and 8) health care insurance. Time was valued according to the
average hourly wage in 2006 in Canada. RESULTS: 670 patients
returned completed questionnaires. The mean annual OPC and
TC of PC care was $1093/patient. Mean annual OPC were
estimated to be $349/patient. Patients incurred an average of
$319 annually for health professional visits and diagnostic tests.
Sixty-nine percent (n = 462) of patients visited at least one health
care professional; 43% visited an urologist, 18% visited a family
physician, and 15% visited a radiation oncologist. Individuals
who visited a radiation oncologist incurred the greatest mean
annual TC ($289), followed by patients who visited an urologist
($223) and family physician ($151). Only 26% of patients were
employed for pay; 5 patients reported difﬁculty working. Mean
annual productivity loss was estimated at $225 per patient.
CONCLUSION: TC associated with work loss does not repre-
sent a major economic burden among PC patients because a
minority are working, and impact among those who work is
modest. OPC, in a country with universal health insurance, is
similar in magnitude to the annual attributable direct medical
costs among stable PC outpatients ($349 vs. $303). Data from
this study will be used, along with outcome data gathered from
the same patients, to develop a Canadian PC policy model.
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EFFECT OF DEMOGRAPHIC FACTORS AND SOCIAL
ECONOMICVARIABLES ON HEALTH CARE RESOURCE
UTILIZATION AND EXPENDITURE FOR BREAST CANCER
PATIENTS USING MEPS 2004
Zhan L, Nair RR, Black CD, Pinto SL, Holiday-Goodman M
The University of Toledo,Toledo, OH, USA
OBJECTIVE: To examine the inﬂuences of demographic and
socioeconomic factors on the health care resource utilization
and expenditure for breast cancer patients in MEPS 2004.
METHODS: A retrospective secondary database study was
conducted using the 2004 Medical Expenditure Panel Survey
(MEPS). Patients with breast cancer  18 years (ICD-9-
CM = 174, 175, V10.3, 233 and CCC code = 024) were included
in the analysis. Poisson regression and Generalized Linear-
Gamma model were employed to examine how demographics
and socioeconomics variables predicted the difference in total
health care resource utilization and total expenditure. In order to
generalize the results to the whole U.S. population, sample
weight from MEPS was utilized. RESULTS: A total of 121 female
patients were included in the study. Approximately 52.9% of
them were over 65 years old; 85.1% were Caucasian women;
52.9% were married; 27.3% had Bachelor’s degree or above;
76.0% were urban; 62.0% were unemployed; 67.8% had high
family income; 97.5% had insurance. Caucasian women in the
age group 50–64, who were living in the rural area and had lower
family income, utilized more health care resources. Employment
and family size were not found to signiﬁcantly inﬂuence health
care resource utilization. CONCLUSION: This study provides
insight into factors related to health care resource utilization and
expenditure. Demographic and socioeconomic factors did inﬂu-
ence health care resource and expenditure differently. This study
may help policy makers in optimal decision-making based on the
factors included in the study. Future studies can look into other
factors such as treatment regimen, stage of the disease to explain
differences in health care resource utilization and expenditure
patterns.
CANCER—Patient-Reported Outcomes
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EARLY DISCONTINUATION OF ADJUVANT ENDOCRINE
TREATMENT OF BREAST CANCER
Bowen KL, Owerbach J
Excellus BlueCross BlueShield, Rochester, NY, USA
OBJECTIVE: To estimate the rate of early discontinuation of
oral adjuvant endocrine therapy by women with early-stage
breast cancer in a commercially insured population. METHODS:
The study sample consists of all women from a commercially
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insured population who underwent mastectomy for breast cancer
then ﬁlled a ﬁrst prescription for an oral adjuvant hormonal
agent (OAHA, deﬁned as tamoxifen or an aromatase inhibitor)
within one year after surgery, and had continuous eligibility for
pharmacy beneﬁts from six months prior to surgery. Patients
were excluded if they had claims coded for distant metastasis or
chemotherapy agents speciﬁc for advanced cancer. Days covered
by OAHA are deduced from dispensed dates and days supplied.
Time to nonpersistence (deﬁned as 180 days without OAHA
coverage) is estimated using a Kaplan-Meier analysis and the
relation assessed between time to nonpersistence and age and
history of cytotoxic adjuvant chemotherapy or radiation therapy
preceding endocrine therapy. RESULTS: A total fo 3654 women
(age mean 59.8, SD 12.4) were identiﬁed who satisﬁed study
criteria, underwent mastectomy between July1998 and Decem-
ber 2006, and had pharmacy beneﬁts eligibility extending
through 2007 or at least 180 days after deduced exhaustion of
last OAHA supply. A total of 33.2% had claims consistent with
cytotoxic adjuvant chemotherapy and 65% had claims for radia-
tion therapy. Including as right-censored patients still receiving
therapy at study end (n = 1516) and those lost to follow-up
(n = 969), the cumulative nonpersistence rate is estimated as
24% at three years. Nonpersistence rates were higher for the
youngest and oldest patients, and lower for patients with a
preceding history of cytotoxic chemotherapy or radiation
therapy. CONCLUSION: It is important to increase understand-
ing of the determinants of persistence with cancer therapies
administered orally for long time periods.
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LEUPROLIDE ACETATE PERSISTENCEVARIES BY AGE IN
PATIENTSWITH PROSTATE CANCER
Fuldeore MJ1, Brook RA2, Smeeding J3, Dabbous OH4
1TAP Pharmaceuticals Products Inc, Lakeforest, IL, USA, 2The JeSTARx
Group, Newfoundland, NJ, USA, 3The JeSTARx Group, Dallas,TX,
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OBJECTIVE: The prevalence of prostate cancer increases with
age. Leuprolide acetate is an efﬁcacious therapy in patients with
prostate cancer. Therapy persistence is essential for desirable
clinical outcomes. METHODS: A retrospective analysis was con-
ducted using the Medstat MarketScan database on a commer-
cially and Medicare aged insured population from 2001–2005.
The MarketScan database collects medical claims, pharmacy
claims, cost, and demographics data. Subjects new to leuprolide
acetate (identiﬁed by J-Code of J9217) in 2002 and no codes in
2001 were followed for 3 years. Compliance was calculated
using the medication possession ratio (MPR = total days supply
obtained/days on therapy). Persistence was characterized by the
number of ﬁlls and the days on therapy (start plus estimated
discontinuation date). Subjects were stratiﬁed into age-range
groups, by those >18 and <51 yr, those >81 yr, and 10-year age
ranges in between (51–60, 61–70, 71–80). Survival rate was
calculated using Kaplan–Meier survival curves. RESULTS: A
total of 1541 men with prostate cancer receiving leuprolide
acetate were included in the study. The average MPR for all ages
was 0.70 (Standard Deviation [SD] = 0.15) and did not change
signiﬁcantly by age. Average months persistence was 15.9
months (SD = 11.8, N = 1541) and generally increased with age
from 10.6 months (SD = 12.4, N = 59) for those 18–50 years;
14.8 months (SD = 13.5, N = 188) for those 51–60 years; 12.5
months (SD = 11.2, n = 302) for those 61–70 years; 16.7 months
(SD = 11.4, N = 718) for those 71–80 years; and 19.8 months
(SD = 10.4, N = 274) for those over 80 years. More than one-
third of patients discontinued by six months of therapy.
CONCLUSION: Leuprolide acetate therapy persistence in-
creased with age. Persistency improvement efforts in younger
patients and during the ﬁrst six months of therapy may result in
better outcomes.
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RACIAL DIFFERENCES IN MEDICATION ADHERENCETO
ADJUVANT HORMONALTHERAPY IN MEDICAID ENROLLED
WOMENWITH PRIMARY BREAST CANCER: A COMPARISON
USINGTWO ESTIMATION METHODOLOGIES
Bhosle MJ1,Anderson RT2, Balkrishnan R1
1The Ohio State University College of Pharmacy, Columbus, OH,
USA, 2Wake Forest University School of Medicine,Winston Salem,
NC, USA
OBJECTIVE: To examine differences in medication adherence to
adjuvant hormonal therapy between white and black patients
with breast cancer using different statistical techniques. The data
source: Linked North Carolina Medicaid claims-Tumor Registry
data (years 1999–2005). METHODS: The study design was a
retrospective cohort study of Medicaid enrollees with breast
cancer newly starting adjuvant hormonal therapy (tamoxifen or
aromatase inhibitor) between years January 2000 to December
2004. Medication adherence [measured as Medication Posses-
sion Ratio (MPR)] was assessed using patients’ prescription reﬁll
records. The Medicaid claims and CCR data were merged using
a probabilistic match algorithm. From the linked data, informa-
tion on patients with ICD-9 codes for primary breast cancer was
extracted. RESULTS: Black patients had a 7% and 9% lower
adherence rate as compared to white patients in the propensity
score and regression method respectively. Stratiﬁcation based on
80% cut-off point for the MPR showed that black patients were
21% less likely to be in the high adherence group. CONCLU-
SION: Results from the propensity score and regression analysis
may agree so closely in this study because there was good overlap
in the distribution of background characteristics for the white
and black women with primary breast cancer enrolled in
Medicaid.
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CLINICAL AND DEMOGRAPHIC PREDICTORS OF QUALITY
OF LIFE IN PROSTATE CANCER SURVIVORS
Bremner KE1, Carcone SM1, Kowgier ME2,Alibhai S1, Laporte A2,
Naglie G3, Krahn MD1
1University Health Network,Toronto, ON, Canada, 2University of
Toronto,Toronto, ON, Canada, 3Toronto Rehabilitation Institute,
Toronto, ON, Canada
OBJECTIVE: To determine predictors of quality of life (QoL)
in community-dwelling prostate cancer (PC) survivors.
METHODS: We derived a population-based sample of PC
patients diagnosed in 1993–4, 1997–8 and 2001–2, residing in
3 geographically diverse areas of Ontario, from the Ontario
Cancer Registry (n = 2749, survivors = 1961). Consenting survi-
vors (n = 851) were mailed questionnaires, including the Health
Utilities Index (HUI 2/3), Patient-Oriented Prostate Utility
Scale [PORPUS-P (psychometric) and PORPUS-Ui (utility)],
Functional Assessment of Cancer Therapy-Prostate (FACT-P),
Prostate Cancer Index (PCI), and a consent form for chart review.
We constructed univariate and multivariate regression models to
determine the effects of patient-, disease-, system-, and symptom-
related variables on QoL. RESULTS: A total of 670 patients
returned completed questionnaires and 620 charts were reviewed
(others lost, destroyed; 597 entered for these analyses). Mean
(SD) PORPUS-P score was 71.78 (14.00), mean PORPUS-Ui
was 0.86 (0.11), mean HUI3 was 0.78 (0.24), and mean FACT-P
was 127.26 (18.40). In univariate analyses with patient-related
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